Jo Van Betsbrugge, PhD

Jo Van Betsbrugge is a synthetic organic chemist with over 20 years of drug discovery and development experience. Jo offers comprehensive Chemistry, Manufacturing & Controls (CMC) support to companies developing small molecule and peptide drugs.

Jo’s career started in 1999 when he created BioQuadrant Pharmaceutical Intermediates Inc, a chemistry-based CDMO specializing in the development of small molecule and peptide drugs. At BioQuadrant, he led the successful execution of over 80 milestone-driven projects for private and public biotech firms. He is also a co-inventor and co-developer of Eli Lilly’s Baqsimi ^TM, a novel intranasal dry powder formulation of glucagon originally developed at BioQuadrant in 2009 on behalf of Locemia Solutions (Canada). Baqsimi received FDA approval in July of 2019.

Jo obtained his PhD degree in organic chemistry from the University of Brussels (Belgium) in 1997. He also received training in cGMP-compliant manufacturing, process validation, and in the preparation of the CMC section for NDAs, CTDs and INDs. He’s a member of the American Chemical Society and the American Association of Pharmaceutical Scientists.